Information Provided By:
Fly News Breaks for December 10, 2019
Dec 10, 2019 | 15:22 EDT
Piper Jaffray analyst Tyler Van Buren said the beta thal and sickle cell updates offered by Bluebird Bio (BLUE) at the ASH medical meeting were "solid as per usual," adding that "LentiGlobin continues to look like a cure for most patients." In terms of myeloma, he believes Bluebird and partner Bristol-Myers (BMY) are "prudent" in accelerating ide-cel development. While admitting he is "tempted to get more constructive at these levels," the ASH updates were "not enough" to alter his stance and he keeps a Neutral rating on Bluebird shares, as he believes "reasonable" estimates for bb2121 are already assumed in the stock price, Van Buren tells investors.
News For BLUE;BMY From the Last 2 Days
May 18, 2022 | 08:20 EDT
Purple Biotech (PPBT) announced the initiation of the Phase 2 portion of its ongoing study of CM24, a first-in-class monoclonal antibody with the potential to treat multiple cancers. The Phase 2 is an open-label, multicenter study in subjects with metastatic pancreatic cancer, PDAC, to evaluate the safety and tolerability of CM24 in combination with the PD-1 inhibitor Opdivo and chemotherapy. The primary study endpoint is to evaluate preliminary efficacy in 2nd line PDAC. The phase 2 portion of the study is being conducted as part of Purple Biotech's clinical collaboration with Bristol Myers Squibb (BMY). The companies together made the determination to prioritize PDAC over non-small cell lung cancer based on the positive interim data. Accordingly, this decision will allow an increase in the number of subjects that will be participating, and will accelerate this part of the study, and the updated timeline to complete this trial is within 2023. "We are thrilled at the progress being made to help move this treatment forward in the clinical trial process for the potential benefit of patients with pancreatic cancer," said Gil Efron, President and CFO of Purple Biotech. "We are thankful for our partners at BMS for collaborating with us on this study and their support. Importantly, the decision to prioritize the PDAC study will extend the cash runway of Purple Biotech through the end of 2024," added Efron.
May 17, 2022 | 07:14 EDT
Virtual Meeting to be held on May 17 hosted by Wolfe Research.